Active	Status	Sponsor type	Region	Phase	Filter
6 Active 1 Inactive 7 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Fisher, Aaron
STRIDES, NCT05490563: - a Clinical Research Study of an Investigational New Drug to Treat Spinocerebellar Ataxia	Terminated	2/3	23	Europe, US, RoW	SLS-005, Placebo	Seelos Therapeutics, Inc.	Spinocerebellar Ataxia Type 3	11/23	11/23
NCT03759678 / 2018-004407-39: N-Acetyl-L-Leucine for Ataxia-Telangiectasia (A-T)	Recruiting	2	39	Europe, US	IB1001, N-Acetyl-L-Leucine	IntraBio Inc	Ataxia Telangiectasia, Louis Bar Syndrome	12/24	03/25
SUNRISE-FA, NCT05445323: Gene Therapy for Cardiomyopathy Associated With Friedreich's Ataxia	Active, not recruiting	1/2	8	US	Low dose LX2006, Mid Dose LX2006, High Dose LX2006	Lexeo Therapeutics	Friedreich Ataxia, Cardiomyopathy, Secondary	09/29	09/29
IDEA, NCT04268147: Instrumented Data Exchange for Ataxia Study	Completed	N/A	128	US		University of Chicago, Pfizer, Biogen, APDM Wearable Technologies	Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia Type 2, Spinocerebellar Ataxia Type 3, Spinocerebellar Ataxia Type 6, Friedreich Ataxia	04/24	06/24
Skigen, Natalie
No trials found
Lim, Chris
No trials found